A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT ‐birch pollen extract for the treatment of allergic rhinitis: results of a phase II study-Reference-Cited by-同舟云学术

A randomized DBPC trial to determine the optimal effective and safe dose of a SLIT ‐birch pollen extract for the treatment of allergic rhinitis: results of a phase II study

Published:2015-10-26 Issue:1 Volume:71 Page:99-107
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Pfaar O.¹²,Twuijver E.³,Boot J. D.³,Opstelten D. J. E.³,Klimek L.¹,Ree R.⁴,Diamant Z.⁵⁶,Kuna P.⁷,Panzner P.⁸

Affiliation:

1. Center for Rhinology and Allergology Wiesbaden Germany

2. Department of Otorhinolaryngology, Head and Neck Surgery Medical Faculty Mannheim Universitätsmedizin Mannheim Heidelberg University Mannheim Germany

3. HAL Allergy BV Leiden The Netherlands

4. Departments of Experimental Immunology and of Otorhinolaryngology Academic Medical Center University of Amsterdam Amsterdam The Netherlands

5. Department of Respiratory Medicine & Allergology Institute for Clinical Science Skane University Hospital Lund Sweden

6. Departments of Clinical Pharmacy & Pharmacology and General Practice University Medical Center Groningen University of Groningen Groningen The Netherlands

7. Dept. of Internal Medicine Asthma and Allergy Medical University of Lodz Lodz Poland

8. Department of Allergology and Immunology Medical Faculty in Plzen Charles University Prague Prague Czech Republic

Funder

AstraZeneca

Boehringer Ingelheim

Meso Scale Diagnostics

Baxter International

Takeda Pharmaceuticals U.S.A.

Grupa Adamed

Chiesi Farmaceutici

GlaxoSmithKline

Novartis